Liquid Biopsy ONLINE Webinar 1: Leveraging Liquid Biopsy for a More Personalised Approach to Cancer Treatment and Monitoring

Join us for ‘Liquid Biopsy ONLINE: From Bench to Bedside’ to hear from the experts how liquid biopsies are poised to improve cancer management as they edge closer to the clinic.

We’ll cover how they’re able to inform treatment decision making, advance MRD detection and provide a multitude of new options for clinicians across the continuum of cancer care.

Our speakers will showcase examples of how such assays are being clinically developed and how the most recent technological innovations are overcoming the most crucial challenges (e.g., sensitivity) which have until now, hindered their widespread use.

Finally, we’ll outline which challenges and considerations remain as we look towards a future of non-invasive cancer diagnosis and how we can overcome them.

Webinar 1: Leveraging Liquid Biopsy for a More Personalised Approach to Cancer Treatment and Monitoring

Tuesday 14th November at 3pm GMT / 4pm CET / 10am EST

This webinar will take you through how scientists are using the latest approaches to prime liquid biopsies as an effective means for detecting cancer risk, recurrence, onset, and progression.

Evaluating the Use of ctDNA to Guide Chemotherapy Treatment Decisions for Colorectal Cancer Patients - Naureen Starling, Principal Investigator and Consultant (Medical Oncology), The Royal Marsden Hospital

Clinical Development of Liquid Biopsy-Based Assays for Children with Solid Tumors - Jaclyn Biegel, Chief of Genomic Medicine and Director for Personalized Medicine, Children’s Hospital Los Angeles

Upcoming webinars in this series:

Webinar 2: Liquid Biopsy for MRD and Resistance Detection.

Tuesday 21st November at 3pm GMT / 4pm CET / 10am EST

Liquid biopsies offer a unique opportunity to detect post-treatment MRD and assess the likelihood of resistance. This offers clinicians vital, actionable information to monitor treatment response and to act quickly with the emergence of resistance.

Join this webinar to learn how the latest liquid biopsy workflows are able to accurately screen for MRD keeping clinicians one step ahead of cancer.

Monitoring MRD in Colorectal Cancer to Advance Precision Medicine – Pashtoon Kasi, Director, Colon Cancer and Precision Medicine Research for Liquid Biopsies, Weill Cornell Medicine

Advancing MRD Detection in Patients with Hematologic Cancers - David Kurtz, Assistant Professor and Group Lead, Stanford University

Defining the Clinical Utility of Liquid Biopsy for MRD Detection in Colon Cancer: The PEGASUS Trial - Sara Lonardi, Head of Oncology, Veneto Institute of Oncology IOV - IRCCS Padua, Italy

Webinar 3: Overcoming Challenges and Establishing the Clinical Utility of Liquid Biopsies

Tuesday 28th November at 3pm GMT / 4pm CET / 10am EST

Scientists can use the information obtained from a liquid biopsy to tailor a patient's treatment to their individual needs so they can get the right treatment at the right time. However, suboptimal sensitivity has slowed the progress of delivering liquid biopsies to patients effectively. But not for much longer…

Learn how the latest methods and technologies are supporting the development of more sensitive and reliable liquid biopsies and discover which considerations still must be considered.

Injectable Priming Agents and Sequencing Technology Innovations to Improve Liquid Biopsy Testing – Viktor Adalsteinsson, Director of the Gerstner Center for Cancer Diagnostics and Lead of the Liquid Biopsy Team, Broad Institute

Clinical Considerations for the Implementation of Liquid Biopsy Testing in Lung Cancer Patients – Paul Hofman, Professor-Clinician and Team Leader, Nice Sophia Antipolis University

“Plasma-first” Approach for Molecular Genotyping in Non-Small Cell Lung Cancer: Opportunities and Challenges – Miguel García-Pardo, Medical Oncologist, Hospital Universitario Ramón y Cajal, Madrid